Valbonne, France, April 13, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, announces today that Stephane Boissel, CEO of TxCell, and other senior management will chair and participate at roundtables, present at and attend, a number of leading scientific conferences during the second quarter of 2016.
TxCell will give updates about the development of its pipeline and technology platforms, including its second platform based on CAR-Tregs, ENTrIA.
These conferences include:
PEGS Summit Boston, April 25-29, Boston, United States
o Arnaud Foussat, CSO of TxCell, will give a presentation entitled ‘Regulatory T Cells-Based Cellular Immunotherapy of Inflammation and Autoimmunity’ on April 26 at 11.20am local time.
World Stem Cells & Regenerative Medicines Congress 2016, May 18-20, London, United Kingdom.
o Stéphane Boissel, CEO of TxCell, will present TxCell’s strategy and latest developments in the ‘Biotech updates’ roundtables on May 19 at 11.25am local time.
o Miguel Forte, COO of TxCell, will participate in the health economics panel entitled ‘Overcoming the reimbursement hurdles in cell and gene therapies globally’ on May 18 at 5pm local time.
ISCT (International Society for Cell Therapy) 2016 Annual Meeting, May 25-28, Singapore
o Two abstracts have been accepted as posters and will be presented by TxCell scientists.
o Miguel Forte will co-chair a plenary session entitled ‘Opportunities and Challenges for Cell Therapy Commercialization in Asia’ on May 28 at 2.55pm local time.
North American Adoptive T Cell Therapy Congress, June 28-30, Boston, United States
o Arnaud Foussat will chair a workshop entitled ‘T-Cell based treatment of inflammation: antigen-specific Treg cells, TCR and CAR engineered Treg cells in transplantation, autoimmunity and chronic inflammatory diseases’ on June 28 at 9am local time.
o Arnaud Foussat will also give a presentation entitled ‘Assessing Regulatory T-Cells as Therapy’ on June 30 at 12pm local time.
About TxCell – www.txcell.com
TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave(R), TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, is expected to enter in clinical studies in the near future. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 49 employees.
These conferences include:
PEGS Summit Boston, April 25-29, Boston, United States
o Arnaud Foussat, CSO of TxCell, will give a presentation entitled ‘Regulatory T Cells-Based Cellular Immunotherapy of Inflammation and Autoimmunity’ on April 26 at 11.20am local time.
World Stem Cells & Regenerative Medicines Congress 2016, May 18-20, London, United Kingdom.
o Stéphane Boissel, CEO of TxCell, will present TxCell’s strategy and latest developments in the ‘Biotech updates’ roundtables on May 19 at 11.25am local time.
o Miguel Forte, COO of TxCell, will participate in the health economics panel entitled ‘Overcoming the reimbursement hurdles in cell and gene therapies globally’ on May 18 at 5pm local time.
ISCT (International Society for Cell Therapy) 2016 Annual Meeting, May 25-28, Singapore
o Two abstracts have been accepted as posters and will be presented by TxCell scientists.
o Miguel Forte will co-chair a plenary session entitled ‘Opportunities and Challenges for Cell Therapy Commercialization in Asia’ on May 28 at 2.55pm local time.
North American Adoptive T Cell Therapy Congress, June 28-30, Boston, United States
o Arnaud Foussat will chair a workshop entitled ‘T-Cell based treatment of inflammation: antigen-specific Treg cells, TCR and CAR engineered Treg cells in transplantation, autoimmunity and chronic inflammatory diseases’ on June 28 at 9am local time.
o Arnaud Foussat will also give a presentation entitled ‘Assessing Regulatory T-Cells as Therapy’ on June 30 at 12pm local time.
About TxCell – www.txcell.com
TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave(R), TxCell’s lead product candidate, is currently in a phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, its second product candidate, for the treatment of autoimmune uveitis, is expected to enter in clinical studies in the near future. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 49 employees.
